title: [Cardiac manifestations of idiopathic hypereosinophilic syndrome].
abstract: BACKGROUND
  The aim of our study is to describe the more common cardiac manifestations of idiopathic hypereosinophilic syndrome representing the major cause of mortality.
  
  
  RESULTS
  Current therapy consists of corticosteroid, hydroxyurea and interferon alpha. Recent publications confirm the activity of imatinib mesylate, a selective tyrosine kinase inhibitor, in patients with idiopathic hypereosinophilic syndrome. In cases with marked valvular compromise or with endomyocardial thrombosis or fibrosis, cardiac surgery can provide substantial benefits.
  
  
  CONCLUSIONS
  A better understanding of the pathophysiology of this syndrome could lead to the development of new therapeutic agents.
authors.affiliation: Service de rhumatologie B , hôpital El-Ayachi, CHU de Rabat-Salé, Maroc. t.harzy@caramail.com
authors.forename: T
authors.initials: T
authors.lastname: Harzy
authors.forename: F
authors.initials: F
authors.lastname: Allali
authors.forename: B
authors.initials: B
authors.lastname: Amine
authors.forename: R
authors.initials: R
authors.lastname: Rahmouni
authors.forename: N
authors.initials: N
authors.lastname: Hajjaj-Hassouni
mesh_terms: D006331:Heart Diseases / Q000209:etiology*; D006801:Humans; D017681:Hypereosinophilic Syndrome / Q000150:complications* / Q000188:drug therapy / Q000503:physiopathology; D011379:Prognosis